Compare GSK plc (GSK) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.44 (market cap $296.92M). The key difference: GSK plc is far larger — about 309.4× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and GSK plc pays a 3.9% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| GSK | YMAG | |
|---|---|---|
Market Cap | $91.88B | $296.92M |
Volume | 7,730,529 | 1,023,545 |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $15.68 |
52-Week Low | $43.24 | $10.76 |
Typical Hold Time | 93 Days | 62 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
YMAG trades at $11.44, down 0.44% on the day, with a bearish technical signal driven by moving averages. The ETF maintains a consistent weekly dividend distribution schedule, with recent payouts ranging from $0.07 to $0.11 per share. Technical indicators show neutral oscillators but bearish momentum signals, with all support and resistance levels clustered around $11.
The outlook remains cautious due to the bearish technical setup and potential NAV volatility from underlying option strategies. Income-focused investors may find the distribution yield attractive, but price stability concerns persist given the concentrated support level and negative momentum indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
